BioCentury
ARTICLE | Clinical News

Dalbavancin: Phase III data

March 4, 2013 8:00 AM UTC

Durata previously reported that dalbavancin met both the FDA- and EMA-defined primary endpoints in the Phase III DISCOVER 1 trial in the indication (see BioCentury, Dec. 17, 2012 & Jan. 21, 2013). Dur...